Back to News
Market Impact: 0.52
Celldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down
Source: Nasdaq
Healthcare & Biotech
Celldex reported positive topline results from two Phase 3 trials of barzolvolimab in chronic spontaneous urticaria (chronic hives). The treatment met its primary endpoint and all key secondary endpoints, materially improving the clinical and regulatory outlook for the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.82
Ticker Sentiment
CLDX0.90
More News
- Why is Celldex Therapeutics stock sliding today?
- Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
- Heidi CEO on AI in Healthcare, $900M valuation
- Guggenheim Names Top Stock Pick in Biotech Sector
- Trump admin says it will save $2.2 billion by kicking off 760,000 Affordable Care Act enrollees over fraud claims
- US and Iran Sit Down for Talks at the UN: Evening Briefing Americas